The Latest Breaking News from Bluebird bio

The U.S. Food and Drug Administration on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

Investors hoping for a revival at the struggling biotech might want to temper their expectations.

 

 

The gene therapy pioneer may earn approval years after initially teasing investors. It may not be time to celebrate.

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

According to Benzinga Pro data, during Q1, bluebird bio (NASDAQ:BLUE) posted sales of $1.95 million. Earnings were up 21.22%, but bluebird bio still reported an overall loss of $122.15 million.

Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings: